Patent Granted for MoAbs Used in Neoprobe's RIGScan Products
DUBLIN, Ohio--Neoprobe Corporation has announced that a patent granted to Jeffrey Schlom, PhD, of the National Cancer Institute, and David Colcher, PhD, of the University of Nebraska Medical Center, covers claims to composition of matter for a large group of second-generation monoclonal antibodies that target the tumor-associated antigen TAG-72.
DUBLIN, Ohio--Neoprobe Corporation has announced that a patentgranted to Jeffrey Schlom, PhD, of the National Cancer Institute,and David Colcher, PhD, of the University of Nebraska MedicalCenter, covers claims to composition of matter for a large groupof second-generation monoclonal antibodies that target the tumor-associatedantigen TAG-72.
Neoprobe holds an exclusive global license for use of these antibodieswith its RIGS technology for surgical detection and treatmentof cancer. The antibodies named in the patent include CC49, acomponent of Neo-probe's first commercial product, RIGScan CR49,currently under investigation for colorectal cancer.
Giredestrant Combo Yields Positive PFS in Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
December 13th 2025“The magnitude of clinical benefit was clinically meaningful and consistent, and was regardless of PIK3CA mutations or alterations in the PIK3CA pathway, duration of prior CDK4/6 inhibitors, including patients who progress within 6 to 12 months, and the choice of prior CDK4/6 inhibitors,” said Hope S. Rugo, MD.
